AstraZeneca Secures Court Injunction Blocking Generic Diabetes Drug Launch in Australia
Key Insights
AstraZeneca won a Federal Court injunction blocking Pharmacor (search) from launching generic versions of diabetes drug dapagliflozin until patent expiry in October 2027.
The court found AstraZeneca established a prima facie case of patent infringement, with the patent covering the active ingredient in blockbuster drug Forxiga.
Dapagliflozin generated $8.5 billion in global revenue for AstraZeneca in 2025 and is expected to be the company's top growth driver in Australia through 2027.
AstraZeneca has secured a significant legal victory in Australia's Federal Court, obtaining an injunction that blocks local generics manufacturer Pharmacor (search) from launching cheaper versions of the diabetes drug dapagliflozin until the company's patent expires in October 2027.
Justice Kylie Downes granted the interlocutory injunction on Monday, restraining Pharmacor (search) from selling, supplying or disposing of multiple dapagliflozin products in Australia. The ruling also requires Pharmacor to withdraw or adjust its pending Pharmaceutical Benefits Scheme (PBS) listing applications for its generic products.
Patent Protection for Blockbuster Diabetes Drug
The patent at issue, AU 2003237886, covers dapagliflozin—the active pharmaceutical ingredient in AstraZeneca's diabetes medication Forxiga. The drug has proven to be a major revenue driver, generating $8.5 billion globally for AstraZeneca in the 2025 financial year and is expected to be the company's number one revenue growth driver in Australia in 2026 and 2027.
Pharmacor (search) had been preparing to launch multiple dapagliflozin-containing products this year through the PBS, which would have triggered a 25 percent reduction in Forxiga's approved ex-manufacturer price and provided Australian patients with significantly cheaper treatment options.
Court's Reasoning and Legal Standards
Justice Downes found that AstraZeneca established a prima facie case of infringement because there was no "factual debate" that Pharmacor (search)'s products fall within the scope of the patent's claims and would be used in a way covered by those claims.
While the court acknowledged that Pharmacor (search)'s principal defense—that the patent is invalid—was arguable, Justice Downes determined it was not sufficiently strong at this preliminary stage to outweigh AstraZeneca's infringement case.
"If Pharmacor (search) were left free to proceed with sales and PBS listings, AstraZeneca's patent monopoly would effectively be destroyed, causing irreparable harm to the company," the judge noted. This harm was found to outweigh Pharmacor's loss of first-mover advantage from an earlier market entry.
Broader Market Implications
The decision has significant implications for Australia's diabetes treatment market. Justice Downes acknowledged that while it was in the interests of the government and community that Forxiga be sold at a cheaper price, the patent system grants monopolies to encourage and reward invention.
"It is therefore in the interests of the Commonwealth, and the public generally, that such invention occurs and is encouraged to continue to occur in the future," she wrote.
The court heard that at least 15 other generic firms have already commenced Australian Register of Therapeutic Goods registration applications for their own dapagliflozin versions, indicating widespread industry interest in entering this market once patent protection expires.
Upcoming Patent Validity Challenge
The more complex legal battle lies ahead, as Pharmacor (search)'s challenge to the patent's validity will be tested in a full trial scheduled to begin in August. The generics company's case centers on familiar pharmaceutical patent litigation arguments, contending that prior art relating to SGLT2 (search) inhibitors—the drug class to which dapagliflozin belongs—anticipated or made obvious the particular compound claimed in AstraZeneca's patent.
Pharmacor (search) also argues that the patent claims extend beyond what was truly disclosed or enabled in the original specification, raising questions about whether the claims are novel and involve an inventive step.
As part of the current ruling, AstraZeneca must provide usual undertakings to compensate any party harmed by the injunction. Both sides have been tasked with proposing a timetable for the substantive case on infringement and invalidity.
With the patent not due to expire until late 2027, the commercial stakes remain significant for both companies and Australian diabetes patients awaiting more affordable treatment options.